ATG9B and central nervous system cancer: The promoter of ATG9B (2 kb upstream of the transcriptional start site) was inserted into the dual‐luciferase reporter plasmid, and glioma cells with ASCL2 overexpression exhibited higher transcriptional activity than those with Ctrl overexpression (Figure 3F).